Coherus Biosciences | CHRS - Assets


Coherus Biosciences reported $258.34M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amarin USD 624.36M 21.4M Jun/2026
Amgen USD 92.5B 1.92B Mar/2026
Baxter International USD 19.79B 55M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Fujifilm JPY 6.05T 170.69B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Pacira USD 1.21B 56.38M Mar/2026
Perrigo USD 7.98B 551.9M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Teva Pharmaceutical Industries USD 39.86B 183M Jun/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026
Zoetis USD 15.15B 313M Mar/2026